A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

BACKGROUND: Comorbidities may contribute to disease activity and treatment response in rheumatoid arthritis (RA) patients. We defined a somatization comorbidity phenotype (SCP) and examined its influence on response to certolizumab pegol (CZP) using data from the PREDICT trial. METHODS: Patients in...

Descripción completa

Detalles Bibliográficos
Autores principales: Curtis, Jeffrey R., Herrem, Christopher, Ndlovu, ’Matladi N., O’Brien, Cathy, Yazici, Yusuf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622491/
https://www.ncbi.nlm.nih.gov/pubmed/28962590
http://dx.doi.org/10.1186/s13075-017-1412-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622491/
https://www.ncbi.nlm.nih.gov/pubmed/28962590
http://dx.doi.org/10.1186/s13075-017-1412-z

Ejemplares similares